A viral protein antibiotic inhibits lipid II flippase activity

Published online:


For bacteriophage infections, the cell walls of bacteria, consisting of a single highly polymeric molecule of peptidoglycan (PG), pose a major problem for the release of progeny virions. Phage lysis proteins that overcome this barrier can point the way to new antibacterial strategies1, especially small lytic single-stranded DNA (the microviruses) and RNA phages (the leviviruses) that effect host lysis using a single non-enzymatic protein2. Previously, the A2 protein of levivirus Qβ and the E protein of the microvirus ϕX174 were shown to be ‘protein antibiotics’ that inhibit the MurA and MraY steps of the PG synthesis pathway2,3,4. Here, we investigated the mechanism of action of an unrelated lysis protein, LysM, of the Escherichia coli levivirus M5. We show that LysM inhibits the translocation of the final lipid-linked PG precursor called lipid II across the cytoplasmic membrane by interfering with the activity of MurJ. The finding that LysM inhibits a distinct step in the PG synthesis pathway from the A2 and E proteins indicates that small phages, particularly the single-stranded RNA (ssRNA) leviviruses, have a previously unappreciated capacity for evolving novel inhibitors of PG biogenesis despite their limited coding potential.

  • Subscribe to Nature Microbiology for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    Fischetti, V. A. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol. 11, 393–400 (2008).

  2. 2.

    Bernhardt, T. G., Wang, I. N., Struck, D. K. & Young, R. Breaking free: “protein antibiotics” and phage lysis. Res. Microbiol. 153, 493–501 (2002).

  3. 3.

    Bernhardt, T. G., Roof, W. D. & Young, R. Genetic evidence that the bacteriophage ϕX174 lysis protein inhibits cell wall synthesis. Proc. Natl Acad. Sci. USA 97, 4297–4302 (2000).

  4. 4.

    Bernhardt, T. G., Wang, I. N., Struck, D. K. & Young, R. A protein antibiotic in the phage Qβ virion: diversity in lysis targets. Science 292, 2326–2329 (2001).

  5. 5.

    Rumnieks, J. & Tars, K. Diversity of pili-specific bacteriophages: genome sequence of IncM plasmid-dependent RNA phage M. BMC Microbiol. 12, 277 (2012).

  6. 6.

    Sham, L. T. et al. Bacterial cell wall. MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. Science 345, 220–222 (2014).

  7. 7.

    Ruiz, N. Bioinformatics identification of MurJ (MviN) as the peptidoglycan lipid II flippase in Escherichia coli. Proc. Natl Acad. Sci. USA 105, 15553–15557 (2008).

  8. 8.

    Mohammadi, T. et al. Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane. EMBO J. 30, 1425–1432 (2011).

  9. 9.

    Elhenawy, W. et al. The O-antigen flippase Wzk can substitute for MurJ in peptidoglycan synthesis in Helicobacter pylori and Escherichia coli. PLoS One 11, e0161587 (2016).

  10. 10.

    Butler, E. K., Davis, R. M., Bari, V., Nicholson, P. A. & Ruiz, N. Structure-function analysis of MurJ reveals a solvent-exposed cavity containing residues essential for peptidoglycan biogenesis in Escherichia coli. J. Bacteriol. 195, 4639–4649 (2013).

  11. 11.

    Kuk, A. C., Mashalidis, E. H. & Lee, S. Y. Crystal structure of the MOP flippase MurJ in an inward-facing conformation. Nat. Struct. Mol. Biol. 24, 171–176 (2017).

  12. 12.

    Butler, E. K., Tan, W. B., Joseph, H. & Ruiz, N. Charge requirements of lipid II flippase activity in Escherichia coli. J. Bacteriol. 196, 4111–4119 (2014).

  13. 13.

    Meeske, A. J. et al. MurJ and a novel lipid II flippase are required for cell wall biogenesis in Bacillus subtilis. Proc. Natl Acad. Sci. USA 112, 6437–6442 (2015).

  14. 14.

    El Ghachi, M. et al. Colicin M exerts its bacteriolytic effect via enzymatic degradation of undecaprenyl phosphate-linked peptidoglycan precursors. J. Biol. Chem. 281, 22761–22772 (2006).

  15. 15.

    Bernhardt, T. G., Struck, D. K. & Young, R. The lysis protein E of ϕX174 is a specific inhibitor of the MraY-catalyzed step in peptidoglycan synthesis. J. Biol. Chem. 276, 6093–6097 (2001).

  16. 16.

    Gorzelnik, K. V. et al. Asymmetric cryo-EM structure of the canonical allolevivirus Qβ reveals a single maturation protein and the genomic ssRNA in situ. Proc. Natl Acad. Sci. USA 113, 11519–11524 (2016).

  17. 17.

    Krishnamurthy, S. R., Janowski, A. B., Zhao, G., Barouch, D. & Wang, D. Hyperexpansion of RNA bacteriophage diversity. PLoS Biol. 14, e1002409 (2016).

  18. 18.

    Shi, M. et al. Redefining the invertebrate RNA virosphere. Nature 540, 539–543 (2016).

  19. 19.

    Osawa, S., Furuse, K. & Watanabe, I. Distribution of ribonucleic acid coliphages in animals. Appl. Environ. Microbiol. 41, 164–168 (1981).

  20. 20.

    Domingo, E., Sabo, D., Taniguchi, T. & Weissmann, C. Nucleotide sequence heterogeneity of an RNA phage population. Cell 13, 735–744 (1978).

  21. 21.

    Domingo, E. & Holland, J. J. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51, 151–178 (1997).

  22. 22.

    Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006.0008 (2006).

  23. 23.

    Miller, J. H. (ed.) in Experiments in Molecular Genetics Ch. 28, 201–205 (Cold Spring Harbor Laboratory, Michigan, 1972).

  24. 24.

    Yunck, R., Cho, H. & Bernhardt, T. G. Identification of MltG as a potential terminase for peptidoglycan polymerization in bacteria. Mol. Microbiol. 99, 700–718 (2016).

  25. 25.

    Cho, H., Uehara, T. & Bernhardt, T. G. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell 159, 1300–1311 (2014).

  26. 26.

    Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).

  27. 27.

    Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725–738 (2010).

Download references


This work was supported by Public Health Service Grant GM27099 to R.Y., by NIH grant AI099144 and CETR U19 AI109764 to T.G.B., by NIH grant R01GM100951 to N.R., and by the American Heart Association under the award number 14POST18480014 to L.-T.S. Additional support for this work was provided by the Center for Phage Technology at Texas A&M University, jointly sponsored by Texas A&M AgriLife. The authors thank H. Rye and L. Kustigian of the Department of Biochemistry and Biophysics, Texas A&M University, for providing purified eGFP standards.

Author information


  1. Center for Phage Technology, Department of Biochemistry and Biophysics, Texas A&M AgriLife Research, Texas A&M University, College Station, TX, 77843-2128, USA

    • Karthik R. Chamakura
    • , Lorna Min
    •  & Ry Young
  2. Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, 02215, USA

    • Lok-To Sham
    • , Hongbaek Cho
    •  & Thomas G. Bernhardt
  3. Department of Microbiology, Ohio State University, Columbus, OH, 43210, USA

    • Rebecca M. Davis
    •  & Natividad Ruiz


  1. Search for Karthik R. Chamakura in:

  2. Search for Lok-To Sham in:

  3. Search for Rebecca M. Davis in:

  4. Search for Lorna Min in:

  5. Search for Hongbaek Cho in:

  6. Search for Natividad Ruiz in:

  7. Search for Thomas G. Bernhardt in:

  8. Search for Ry Young in:


K.R.C., N.R., T.G.B. and R.Y. designed the study and the analysed results. K.R.C. performed genetic selections and microscopy, and constructed strains and plasmids. L.-T.S. performed ColM assays and performed the amJ rescue experiment. R.M.D. constructed various murJ haploid strains, performed their function and expression tests, and performed SCAM. L.M. performed lysis profiles of the LysM-resistant alleles and assisted in making the figures. H.C. constructed the E. coli multi-copy library. K.R.C., T.G.B. and R.Y. prepared the manuscript. N.R. and L.-T.S. edited the manuscript and provided text.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Thomas G. Bernhardt or Ry Young.

Electronic supplementary material

  1. Supplementary Information

    Supplementary Tables 1–4, Supplementary Figures 1–12, Supplementary References.

  2. Life Sciences Reporting Summary